RAN

GTP-binding nuclear protein Ran · P62826 · RAN on Sugi Atlas →

0 patent compounds predicted against RAN, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to RAN by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Does Aldosterone Cause Hypertension by a Non-Renal Mechanism? PHASE4UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients PHASE1/PHASE2COMPLETED
Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47) PHASE1/PHASE2NOT_YET_RECRUITING
Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma PHASE1/PHASE2RECRUITING
Tianasen (ASO-GNAO1) for GNAO1-Encephalopathy With Epilepsy and Movement Disorders. PHASE1/PHASE2RECRUITING
Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Role of the Nuclear Pore Component RANBP2 in Inflammatory Responses to Viral Infections nanCOMPLETED
A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma(SELINA) nanRECRUITING
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Steroid Treatment of Idiopathic Nephrotic Syndrome nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Genetic Analysis of Gray Platelet Syndrome nanCOMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC) nanCOMPLETED
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients nanCOMPLETED
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults nanCOMPLETED
Value of MicroRNA30a in Philadelphia Positive Leukemic Patients nanUNKNOWN
Study of Proteins in Head and Neck Cancer Cells nanCOMPLETED
Molecular Analysis Of Solid Tumors nanRECRUITING
Amyotrophic Lateral Sclerosis (ALS) Families Project nanRECRUITING
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma nanACTIVE_NOT_RECRUITING
Effects of Cardiac Rehabilitation on High Mobility Group Box-1 Levels After Acute Myocardial Infarction nanCOMPLETED
The Roles of Neutrophil Elastase in Lung Cancer nanUNKNOWN
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress nanWITHDRAWN
Role of Geminin and Mcm-2 in Prognosis of Renal Cell Carcinoma nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a RAN binder may also engage these)

ProteinNameSimilarity
P62828 1.000 P62828 →
P62827 1.000 P62827 →
P62825 1.000 P62825 →
Q4R4M9 1.000 Q4R4M9 →
Q6GL85 1.000 Q6GL85 →
P42558 1.000 P42558 →
Q3T054 1.000 Q3T054 →
Q5R556 1.000 Q5R556 →
Q74ZA9 1.000 Q74ZA9 →
Q8K586 1.000 Q8K586 →
P52301 1.000 P52301 →
Q6FR65 1.000 Q6FR65 →
P28748 1.000 P28748 →
P32835 1.000 P32835 →
P54766 1.000 P54766 →
P32836 1.000 P32836 →
P38542 1.000 P38542 →
Q61820 1.000 Q61820 →
P54765 1.000 P54765 →
P79735 1.000 P79735 →
A2Y7R5 1.000 A2Y7R5 →
Q7GD79 1.000 Q7GD79 →
Q69XM7 1.000 Q69XM7 →
A2YEQ6 1.000 A2YEQ6 →
P41919 1.000 P41919 →
O17915 1.000 O17915 →
Q7ZZX9 1.000 Q7ZZX9 →
Q9P4E9 1.000 Q9P4E9 →
Q9YGC0 1.000 Q9YGC0 →
Q8H156 1.000 Q8H156 →